Reinhold Munker — University of Kentucky

If you made any changes in Pure these will be visible here soon.

Education/Academic qualification

Doctor of Medicine, Other Institution

1979

1 Finished
7 Active

22-LEUK-21-NP (CABL001AUS08): A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase-Chronic Myelogenous Leukemia (ASC2ESCALATE)
Munker, R.
Novartis (domestic)
2/3/23 → 12/13/23
Project: Research project
22-HEM-19-MSD: A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
Munker, R.
Merck Sharp & Dohme Corporation
1/23/23 → 11/2/23
Project: Research project
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)
Munker, R.
IQVIA RDS Incorporated
9/29/21 → 6/28/23
Project: Research project
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Munker, R.
IQVIA RDS Incorporated
8/31/21 → 4/24/23
Project: Research project
Phase III, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia In Chronic Phase
Munker, R.
Novartis (domestic)
8/17/21 → 10/30/23
Project: Research project